Renaissance Technologies LLC Reduces Stock Holdings in Candel Therapeutics, Inc. (NASDAQ:CADL)

Renaissance Technologies LLC reduced its position in shares of Candel Therapeutics, Inc. (NASDAQ:CADL) by 63.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,600 shares of the company’s stock after selling 36,305 shares during the period. Renaissance Technologies LLC’s holdings in Candel Therapeutics were worth $128,000 at the end of the most recent quarter.

Separately, Rhumbline Advisers purchased a new stake in Candel Therapeutics in the second quarter valued at approximately $143,000. 13.93% of the stock is owned by institutional investors.

Candel Therapeutics Stock Performance

Shares of Candel Therapeutics stock opened at $6.02 on Monday. The stock has a market capitalization of $179.13 million, a price-to-earnings ratio of -4.70 and a beta of -0.95. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.62 and a quick ratio of 1.62. The business has a 50-day moving average of $6.28 and a 200 day moving average of $6.75. Candel Therapeutics, Inc. has a 12 month low of $0.66 and a 12 month high of $14.30.

Candel Therapeutics (NASDAQ:CADL) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.74) earnings per share for the quarter. As a group, sell-side analysts forecast that Candel Therapeutics, Inc. will post -0.91 earnings per share for the current year.

Insider Buying and Selling

In other Candel Therapeutics news, insider Charles Schoch sold 9,884 shares of the business’s stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $6.47, for a total value of $63,949.48. Following the transaction, the insider now directly owns 62,520 shares of the company’s stock, valued at approximately $404,504.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Candel Therapeutics news, insider Charles Schoch sold 9,884 shares of the company’s stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $6.47, for a total value of $63,949.48. Following the sale, the insider now owns 62,520 shares of the company’s stock, valued at approximately $404,504.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CTO Seshu Tyagarajan sold 14,851 shares of the firm’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $6.47, for a total transaction of $96,085.97. Following the transaction, the chief technology officer now directly owns 146,049 shares of the company’s stock, valued at approximately $944,937.03. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 49,063 shares of company stock worth $318,122 in the last 90 days. Company insiders own 41.60% of the company’s stock.

Candel Therapeutics Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.